Top Markets
#1 MowCat MowCat +49.07%
#2 Velvet Velvet +36.37%
#3 Derive Derive +21.24%
#4 Quack AI Quack AI +19.75%
#5 Audiera Audiera +19.69%
#6 MarsCoin MarsCoin +16.65%
#7 Bermuda Shorts Bermuda Shorts +16.51%
#8 aPriori aPriori +15.29%
#9 Biconomy Biconomy +13.82%
#10 Geodnet Geodnet +12.49%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Medigene AG Medigene AG

Medigene AG

MDG1
Rank in Stocks #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Share Price
$0.14942078
Last synced: 2025-05-15
Market Cap
$3.86M
Change (1 day)
0.10%
Change (1 year)
0.00%
Country
DE
Trade Medigene AG (MDG1)

Category

Healthcare
P/S ratio for Medigene AG (MDG1)
P/S ratio as of August 2026 TTM: 0.33
According to Medigene AG latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.33. At the end of 2022 the company had a P/S ratio of 1.58.
P/S ratio history for Medigene AG from 2004 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.33 -94.44%
2023 5.86 270.74%
2022 1.58 -76.40%
2021 6.70 -37.67%
2020 10.75 15.55%
2019 9.30 -81.25%
2018 49.61 -30.09%
2017 70.97 -38.41%
2016 115.23 29.31%
2015 89.11 1,204.14%
2014 6.83 -18.93%
2013 8.43 -29.80%
2012 12.01 -23.25%
2011 15.64 -52.41%
2010 32.87 915.33%
2009 3.24 -25.83%
2008 4.36 -43.78%
2007 7.76 51.85%
2006 5.11 -35.56%
2005 7.93 -16.62%
2004 9.52 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 3,018.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 3,006.19%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 1,354.31%
BE